BioNTech Expands COVID-19 Vaccine Output Again, Forecasts $10bn Revenues

Also Increasing Oncology Trials

 
• By Andrew McConaghie

Success of the vaccine will fuel the company’s push into immunotherapy, as it reported first commercial sales.

Mainz, Rheinland-Pfalz, Germany-9. September 2020 Biontech building in Mainz with the sun shining and waving flags
BioNTech has been transformed into a European biotech powerhouse, with a market cap of $26bn and vaccines revenues to fund its ambitions in immunotherapy.

More from Business

More from Scrip